MedTrace Logo

Comparing Haloperidol and Olanzapine in Treating Terminal Delirium

NCT04750395 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-03-01

No results posted yet for this study

Summary

As patients with terminal illness enter the dying phase, they may experience symptoms of restlessness, agitation, or cognitive disturbance, known as terminal delirium. In community care, pharmacological therapies are utilized to manage the syndrome, the most commonly used being neuroleptics haloperidol and olanzapine.

However, there is currently a dearth of studies on the efficacy and safety between haloperidol and olanzapine in the community palliative care setting; existing studies involve non-terminal patients in the hospital suffering from acute delirium. To fill this gap, an open-label randomized clinical trial is proposed to compare the effects of haloperidol and olanzapine in the management of terminal delirium in home hospice patients who are imminently dying. Key outcome measures are the reduction of delirium symptoms and the reduction of agitation. Secondary outcome is comparing the adverse effect burden on patients.

Conditions

  • Delirium
  • Terminal Illness

Interventions

DRUG

Haloperidol Solution

Oral transmucosal haloperidol solution 2.5mg

DRUG

Olanzapine Tablets

Oral transmucosal olanzapine tablet 5.0mg

Sponsors & Collaborators

  • HCA Hospice Care

    lead OTHER

Principal Investigators

  • Poh Heng Chong, MD · HCA Hospice Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750395 on ClinicalTrials.gov